JP2003515583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515583A5 JP2003515583A5 JP2001541859A JP2001541859A JP2003515583A5 JP 2003515583 A5 JP2003515583 A5 JP 2003515583A5 JP 2001541859 A JP2001541859 A JP 2001541859A JP 2001541859 A JP2001541859 A JP 2001541859A JP 2003515583 A5 JP2003515583 A5 JP 2003515583A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- oxy
- methylsulfonyl
- ethoxy
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 4
- KJJASSOVFFYOHM-SANMLTNESA-N (2s)-3-[3-benzyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=CC=CC=1CC1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 KJJASSOVFFYOHM-SANMLTNESA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- KJJASSOVFFYOHM-AREMUKBSSA-N (2r)-3-[3-benzyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=CC=CC=1CC1=CC(C[C@@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 KJJASSOVFFYOHM-AREMUKBSSA-N 0.000 description 1
- JOZJRLWJUJMJOG-UHFFFAOYSA-N 2-ethoxy-3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 JOZJRLWJUJMJOG-UHFFFAOYSA-N 0.000 description 1
- ULPLXYRZURGOJB-UHFFFAOYSA-N 2-ethoxy-3-[3-methoxy-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid Chemical compound COC1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 ULPLXYRZURGOJB-UHFFFAOYSA-N 0.000 description 1
- CBUGXMQJNKGCIB-UHFFFAOYSA-N 2-ethoxy-3-[4-[2-(4-hydroxyphenyl)ethoxy]-3-methylphenyl]propanoic acid Chemical compound CC1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(O)C=C1 CBUGXMQJNKGCIB-UHFFFAOYSA-N 0.000 description 1
- QHBGILWAQKUUAU-UHFFFAOYSA-N 2-ethoxy-3-[4-methoxy-3-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(OC)C(OCCC=2C=CC(OS(C)(=O)=O)=CC=2)=C1 QHBGILWAQKUUAU-UHFFFAOYSA-N 0.000 description 1
- KJJASSOVFFYOHM-UHFFFAOYSA-N 3-[3-benzyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=CC=CC=1CC1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 KJJASSOVFFYOHM-UHFFFAOYSA-N 0.000 description 1
- YRJFDAZUSIHIQN-UHFFFAOYSA-N 3-[3-benzyl-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=CC=CC=1CC1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 YRJFDAZUSIHIQN-UHFFFAOYSA-N 0.000 description 1
- WBHUENAVXUPZDB-UHFFFAOYSA-N 3-[3-tert-butyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound CC(C)(C)C1=CC(CC(OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 WBHUENAVXUPZDB-UHFFFAOYSA-N 0.000 description 1
- QJSQEBHZCMIOPS-UHFFFAOYSA-N 3-[4-benzyl-3-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=C(OS(C)(=O)=O)C=CC=1CCOC1=CC(CC(OCC)C(O)=O)=CC=C1CC1=CC=CC=C1 QJSQEBHZCMIOPS-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AGRHJQXOIQIFEC-MUUNZHRXSA-N ethyl (2r)-3-[3-benzyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C=1C=CC=CC=1CC1=CC(C[C@@H](OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 AGRHJQXOIQIFEC-MUUNZHRXSA-N 0.000 description 1
- KHPNEQHXWHMNMU-UHFFFAOYSA-N ethyl 2-ethoxy-3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoate Chemical compound CC(C)(C)OC(=O)NC1=CC(CC(OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 KHPNEQHXWHMNMU-UHFFFAOYSA-N 0.000 description 1
- BBWNOQNAOOHWFZ-UHFFFAOYSA-N ethyl 2-ethoxy-3-[3-methyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoate Chemical compound CC1=CC(CC(OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 BBWNOQNAOOHWFZ-UHFFFAOYSA-N 0.000 description 1
- AGRHJQXOIQIFEC-UHFFFAOYSA-N ethyl 3-[3-benzyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C=1C=CC=CC=1CC1=CC(CC(OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 AGRHJQXOIQIFEC-UHFFFAOYSA-N 0.000 description 1
- CRLZXWDQKKYSSP-UHFFFAOYSA-N ethyl 3-[3-benzyl-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C=1C=CC=CC=1CC1=CC(CC(OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 CRLZXWDQKKYSSP-UHFFFAOYSA-N 0.000 description 1
- DYZWJGGNBISGJS-UHFFFAOYSA-N ethyl 3-[3-tert-butyl-4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound CC(C)(C)C1=CC(CC(OCC)C(=O)OCC)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 DYZWJGGNBISGJS-UHFFFAOYSA-N 0.000 description 1
- VLJZDMUHOYNAJU-UHFFFAOYSA-N ethyl 3-[4-benzyl-3-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C=1C=C(OS(C)(=O)=O)C=CC=1CCOC1=CC(CC(OCC)C(=O)OCC)=CC=C1CC1=CC=CC=C1 VLJZDMUHOYNAJU-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- SBKOOFCHZBMKBM-UHFFFAOYSA-N propan-2-yl 3-[4-benzyl-3-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C=1C=C(OS(C)(=O)=O)C=CC=1CCOC1=CC(CC(OCC)C(=O)OC(C)C)=CC=C1CC1=CC=CC=C1 SBKOOFCHZBMKBM-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012453 solvate Chemical group 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9904421A SE9904421D0 (sv) | 1999-12-03 | 1999-12-03 | New compounds |
| SE9904421-6 | 1999-12-03 | ||
| PCT/SE2000/002385 WO2001040172A1 (en) | 1999-12-03 | 2000-11-29 | New tri-substituted phenyl derivatives and analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515583A JP2003515583A (ja) | 2003-05-07 |
| JP2003515583A5 true JP2003515583A5 (https=) | 2007-09-06 |
Family
ID=20417986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541859A Pending JP2003515583A (ja) | 1999-12-03 | 2000-11-29 | 新規三置換フェニル誘導体および類似体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6750252B2 (https=) |
| EP (1) | EP1237856B1 (https=) |
| JP (1) | JP2003515583A (https=) |
| KR (1) | KR100787072B1 (https=) |
| CN (1) | CN1206212C (https=) |
| AR (1) | AR033957A1 (https=) |
| AT (1) | ATE266633T1 (https=) |
| AU (1) | AU766533B2 (https=) |
| BR (1) | BR0016130A (https=) |
| CA (1) | CA2392039A1 (https=) |
| DE (1) | DE60010747T2 (https=) |
| DK (1) | DK1237856T3 (https=) |
| ES (1) | ES2219425T3 (https=) |
| IL (2) | IL149517A0 (https=) |
| MX (1) | MXPA02005223A (https=) |
| MY (1) | MY124727A (https=) |
| NO (1) | NO20022590L (https=) |
| PT (1) | PT1237856E (https=) |
| SE (1) | SE9904421D0 (https=) |
| TR (1) | TR200401716T4 (https=) |
| TW (1) | TWI224590B (https=) |
| WO (1) | WO2001040172A1 (https=) |
| ZA (1) | ZA200203798B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280574A (zh) | 1997-10-27 | 2001-01-17 | 雷迪研究基金会 | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 |
| AU749505B2 (en) | 1997-10-27 | 2002-06-27 | Dr. Reddy's Laboratories Limited | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| AU752059B2 (en) | 1997-10-27 | 2002-09-05 | Dr. Reddy's Laboratories Limited | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| US6531596B1 (en) | 1998-10-29 | 2003-03-11 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of new antidiabetic agents |
| AU763087B2 (en) | 1998-10-29 | 2003-07-10 | Dr. Reddy's Laboratories Limited | An improved process for the preparation of new antidiabetic agents |
| US6897199B2 (en) | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
| SE0101386D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
| US20110105748A1 (en) * | 2001-10-16 | 2011-05-05 | Debnath Bhuniya | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| UA82835C2 (en) * | 2001-12-03 | 2008-05-26 | Reddys Lab Ltd Dr | ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2872159B1 (fr) * | 2004-06-28 | 2007-10-05 | Merck Sante Soc Par Actions Si | Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete |
| TW200817369A (en) * | 2006-05-22 | 2008-04-16 | Elan Pharm Inc | Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds |
| AU2008221673B2 (en) | 2007-03-08 | 2013-03-28 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| FR2917084B1 (fr) * | 2007-06-05 | 2009-07-17 | Galderma Res & Dev | Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques. |
| FR2917086B1 (fr) | 2007-06-05 | 2009-07-17 | Galderma Res & Dev | Nouveaux derives d'acide 3-phenyl acrylique activateurs des recepteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques. |
| DE102007038251A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| SE9801990D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
-
1999
- 1999-12-03 SE SE9904421A patent/SE9904421D0/xx unknown
-
2000
- 2000-11-21 TW TW089124657A patent/TWI224590B/zh not_active IP Right Cessation
- 2000-11-29 IL IL14951700A patent/IL149517A0/xx active IP Right Grant
- 2000-11-29 TR TR2004/01716T patent/TR200401716T4/xx unknown
- 2000-11-29 BR BR0016130-6A patent/BR0016130A/pt not_active Application Discontinuation
- 2000-11-29 PT PT00983619T patent/PT1237856E/pt unknown
- 2000-11-29 DK DK00983619T patent/DK1237856T3/da active
- 2000-11-29 CN CNB008163812A patent/CN1206212C/zh not_active Expired - Fee Related
- 2000-11-29 EP EP00983619A patent/EP1237856B1/en not_active Expired - Lifetime
- 2000-11-29 WO PCT/SE2000/002385 patent/WO2001040172A1/en not_active Ceased
- 2000-11-29 CA CA002392039A patent/CA2392039A1/en not_active Abandoned
- 2000-11-29 DE DE60010747T patent/DE60010747T2/de not_active Expired - Fee Related
- 2000-11-29 AU AU20351/01A patent/AU766533B2/en not_active Ceased
- 2000-11-29 KR KR1020027007057A patent/KR100787072B1/ko not_active Expired - Fee Related
- 2000-11-29 MX MXPA02005223A patent/MXPA02005223A/es active IP Right Grant
- 2000-11-29 AT AT00983619T patent/ATE266633T1/de not_active IP Right Cessation
- 2000-11-29 JP JP2001541859A patent/JP2003515583A/ja active Pending
- 2000-11-29 ES ES00983619T patent/ES2219425T3/es not_active Expired - Lifetime
- 2000-11-29 US US10/148,850 patent/US6750252B2/en not_active Expired - Fee Related
- 2000-11-30 MY MYPI20005602A patent/MY124727A/en unknown
- 2000-12-01 AR ARP000106386A patent/AR033957A1/es not_active Application Discontinuation
-
2002
- 2002-05-07 IL IL149517A patent/IL149517A/en not_active IP Right Cessation
- 2002-05-13 ZA ZA200203798A patent/ZA200203798B/en unknown
- 2002-05-31 NO NO20022590A patent/NO20022590L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003515583A5 (https=) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| GEP20063875B (en) | Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist | |
| RU2002135312A (ru) | Средство, усиливающие секрецию гормона роста | |
| JP2007502806A5 (https=) | ||
| RU98102959A (ru) | Замещенные бензиламинопиперидины | |
| JP2008521827A5 (https=) | ||
| JP2002509153A5 (https=) | ||
| CA2377174A1 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| JP2003503449A5 (https=) | ||
| MY125099A (en) | Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid | |
| MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
| JP2002539089A5 (https=) | ||
| CA2499721A1 (en) | Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists | |
| JP2004538314A5 (https=) | ||
| JPH1036365A5 (https=) | ||
| BR0009080A (pt) | Método de tratamento da apnéia do sono | |
| DE69722610D1 (de) | Neue Inhalationspräparate enthaltend CR 2039 (Andolast) | |
| JP2007512387A5 (https=) | ||
| JP2003500466A5 (https=) | ||
| JP2004501888A5 (https=) | ||
| NO991164L (no) | Farmas°ytisk preparat for behandling av virussykdommer | |
| JP5650642B2 (ja) | メチオニンアナログおよびそれらを使用する方法 | |
| SE9904412D0 (sv) | Comminuted form | |
| CA2418227A1 (en) | Process for the preparation of 5-hydroxymethyl 2-oxazolidinone and novel intermediate |